Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist SELARL CABINET DOCTEUR GONZALEZ 27, Boulevard des Minimes 31 200 Toulouse! 05 34 40 77 30 e-mail : cabinet.dr.gonzalez@wanadoo.fr Fax : 05 34 40 77 33 PRESENT PROFESSIONAL POSITION OPHTALMOLOGIST DOCTOR, Private practice Retinal medical Specialist, AMD in particular Installation year : 1988 TRAINING (1976-1986) : General Medical Practice and SPECIALITY 1977 : Human Biology Grade 1987 Medical Doctor Degree THESIS : Macular sub-retinal neovascularisation and its treatment with Krypton laser. General review, computer clinical and angiographical study. Treatment results for the 85 studied cases. CES of OPHTHALMOLOGY, Ophthalmology Medical Specialist Degree PROFESSIONAL EXPERIENCE Since 1988 01/01/2014 Private practice Ophthalmology, Retinal Medical Specialty and AMD, private office Marked by a dot and underlined, underneath are the medical exams,which I have been the first to introduce in the Region Midi Pyrénées Angiographies : - FA (Fluorescein Angiography), since 1988 - ICG (Infracyanin Green Angiography), since 1992 - SPECTRALIS and SPECTRALIS OCT Angiography, since 2007 Until now I have been the only physician in the Midi Pyrénées Region to have a common practice of Spectralis system FA and ICG, retinal and optic nerve Spectral domain OCT. Laser : all types, including multi waves,since 1988 OCT 3 (Optic Confocal Tomography), since 1995 Photodynamic Therapy, since 2000 IVT (Intra-Vitreal Injection),1 er surgical unit in Private office in Midi-Pyrénées, since 2005 (only 10 surgical units like this in France) HIV ophthalmologic Pathology 1
Contactology RESEARCH BACKGROUND Fundamental Research 1989 1991 Professeur Soleihavoup Laboratory ( Histo-Cytology department, Purpan CHU Toulouse) Antikératin antibody profiling of retinal pigment epithelium. publication about this work : n 20 reference below Based on the results obtained during this period, I submitted many working hypothesis about ARMD etiopathogenesis, with the specific retinal pigment epithelium role and in particular mitochondrial pigment epithelium dysfunction. Those hypothesis were based on regular scientific literature revue and clinical studies published in an international way by well known teams. At this time, I have established links with other researchers in the course of many meetings. Interest for a coordinated research These contacts referred to above have for a few of them become permanent and I am looking for teams able to cooperate together in order to demonstrate and confirm those hypothesis. I would like to federate several research teams to make them more dynamic and productive. The basic idea is to get them together, taking advantage of their specific competences, cross fertilize between the groups with a common goal which is to better understand AMD pathogenesis and more over retinal pathologies. In this respect, it is a common feature of the pharma industry that research is terribly expensive and that a lot of duplication is going on, at a tremendous cost. I believe that, as it is presently done for ALZHEIMER s disease, where a number of pharma companies are beginning to work on a common project, the same kind of research could be developed for AMD, because it is simply not true that fundamental research is competitive in the economic sense of the word. In particular, findings of toxicity in the research programs should be shared between the companies, which would improve the speed at which innovation can be brought into the sector. This could also be a very interesting topic for a joint funding between the industry and the EU Research and Development Framework Programme. Clinical Research Absolutely aware of the scientific progress importance in medical practice, and always seeking for innovation, I ve been precursor : - In the retinal pathologies investigative techniques use (cf ref n 8,26,28,30,33) - In the therapeutic principles use : PED treatment (cf ref n 15), «Baxter» principle use development for CMV retinitis treatment, of Thalidomide, for SIDA patients (cf ref n 22,27) - In new treatments development : no steroid anti-inflammatory treatments in general and/or subconjunctival administration to treat exudative reactions and complications of ADM, Diabetic retinopathy, retinal vein occlusion (cf ref n 1, 2,3) - In new therapeutic protocol suggestions : retrofoveolar neovascular AMD complication treated with series of 3 IVT (cf ref n 9,10,11,12,4,5,6). Others international medical teams have confirmed this 2
protocol, with similar results, much better and promising than those of other standard studies. (cf ARVO 2010 meeting abstracts and conferences) - In having initiative in protocol and therapies : in contrast with usual practice, I recommend not to give Triamcinolone by IVT for the treatment of exudative reaction complicating AMD, Diabetic retinopathy, retinal vein occlusion ( now quite dropped method ) - In my medical practice of Ophthalmology : private practice, no in clinic and/or hospital, with surgical unit in the office SCIENTIFIC AND CLINICAL WORKS (published and /or presented in meetings) Internationals 1 - Diclofenac with photodynamic therapy for choroidal neovascularisation complicating AMD C Gonzales, ARVO 2005 and Mickaelson Meeting 2005 2 - Subconjonctival injection of triamcinolone and photodynamic therapy (PDT) for exsudative choroidal neovascularisation (CNV) complicating age macular degeneration (AMD) C Gonzalez, ARVO 2006 et Euretina 2007 3 - Subconjonctival injection of triamcinolone for the treatment of macular oedema complicating diabetic retinopathy C Gonzalez, ARVO 2007 4 - Intravitreal pegaptanib for retrofoveolar neovascular myopia maculopathy C Gonzalez, ARVO 2008 5 - Intravitreal pegaptanib for retrofoveolar neovascularisation complicating age macular degeneration (AMD), with predominant pigment epithelium(pe) atrophic areas C Gonzalez, Euretina 2008 6 - Analysis of intravitreal ranibizumab injections effects on exudative reaction complicating subfoveal choroidal neovascular age related macular degeneration (AMD) C Gonzalez, EVER 2008 7 - No functional vision improvement after intravitreal ranibizumab injections (IVT) for retrofoveolar choroidal neovascular age related macular degeneration (AMD),why? C Gonzalez, EVER 2008 8 - Interest of spectralis HRA + OCT for the follow-up of age macular degeneration (AMD),with and without neovascular complication C Gonzalez, Heidelberg meeting 2009 9 - Treatment of retrofoveolar neovascular AMD by series of 3 ranibizumab injections,1 year ½ follow-up 10 - Treatment of retrofoveolar neovascular AMD by 3 injections series of ranibizumab followed by maintenace treatment with 3 pegaptanib IVT after 1 year follow-up 11 - Treatment of retrofoveolar neovascular AMD by series of 3 ranibizumab injections,1 year ½ follow-up 12 - Treatment of retrofoveolar neovascular AMD by 3 injections series of ranibizumab followed by maintenace treatment with 3 pegaptanib IVT after 1 year follow-up 13 - Intravitreal pegaptanib for retrofoveolar neovascular age related macular degeneration, in pseudo vitelliform and/or drusenoid pigment epithelium detachment shape C Gonzalez, SOE 2009 14 - Intravitreal ranibizumab for retrofoveolar neovascular age related macular degeneration, in pseudo vitelliform and/or drusenoid pigment epithelium detachment shape C Gonzalez, SOE 2009 15 - Treatment of retrofoveolar neovascular AMD by series of 3 ranibizumab injections, 1 year ½ follow-up C Gonzalez, EVER 2009 3
16 - Treatment of focal and/or diffuse central serous chorioretinopathy by series of 3 intravitreal injections of ranibizumab C Gonzalez, EURETINA 2010 17 - Treatment of macular retinal telangiectasies type 1 by series of 3 ranibizumab injections after 1 year follow-up C Gonzalez, EURETINA 2010 18 - Series of 3 ranibizumab injections, for the treatment of retrofoveolar neovascular age related macular degeneration, 2 ½ years follow-up C Gonzalez, EVRS 2010 19 - Treatment of Type 1 idiopathic Macular Telangiectasia by series of 3 Ranibizumab injections after 1 year follow-up C Gonzalez, EVRS 2010 20 - Treatment of type 1 idiopathic macular telangiectasia by series of 3 intravitreal injections of ranibizumab C Gonzalez, EVER 2010 21 - AMD edemas: diagnosis, follow-up, therapeutic, prognosis, spectral domain oct, angiography, icg interests C Gonzalez, EVER 2010 22 - Treatment of focal and/or diffuse central serous chorioretinopathy by series of 3 intravitreal injections of ranibizumab C Gonzalez, EVER 2010 23 - Treatment of diabetic retinopathy macular edema by series of 3 ranibizumab injections after 2 years ½ follow-up C Gonzalez, EURETINA 2011 24 - Treatment of retinal vein occlusion by series of 3 ranibizumab intravitreal injections C Gonzalez, EURETINA 2011 25 - Intravitreal injections of ranibizumab for retrofoveolar neovascular age related macular degeneration, in pseudo vitelliform and/or drusenoid pigment epithelium detachment shape C Gonzalez, EVER 2011 26 - Retinal vein occlusion: treatment by series of 3 ranibizumab ivt C Gonzalez, EVER 2011 27 - Diabetic retinopathy macular edema: treatment by series of 3 intravitreal ranibizumab injections after 3 years follow-up C Gonzalez, EVER 2011 28 - Atrophic areas and neovascular AMD: characteristics, evolution of atrophic lesions, during protocol treatment by series of 3 ranibizumab ivt, 4 years follow-up C Gonzalez, ARVO 2012 29 - Neovascular AMD with atrophic areas. characteristics, evolution of atrophic lesions associated to neovascular AMD treated by series of 3 ranibizumab ivt protocol, 4 years follow-up C Gonzalez, EURETINA 2012 30 - AMD atrophic areas. characteristics, evolution study, and its interest.3 years follow-up C Gonzalez, EURETINA 2012 31 - Atrophic areas and/withneovascular AMD.Characteristics,evolutionof atrophic lesions associatedto neovascular AMD treated by series of 2 ranibizumabivt protocol, 4 years follow-up C Gonzalez, EVER 2012 32 - Age macular degeneration-alzheimer disease: relevance and interest of ophthalmologic exam in detection and follow-up of Alzheimer disease C Gonzalez, EVER 2012 33 - AMD atrophic areas. Characteristics, evolution study, and its interest. 3 years follow-up C Gonzalez, EVER 2012 34 - Ophthalmologic exam in Age Macular Degeneration-Alzheimer Disease:its interest in detection, follow-up of AMD, of Alzheimer disease, its relevance to highlight the links and correlations between AMD and AD C Gonzalez, ARVO 2013 35 - Age Macular Degeneration- Alzheimer Disease : Relevance and Interest of OCT, OCT en face exam in detection and in follow-up of AMD and Alzheimer Disease C Gonzalez, EURETINA 2013 36 - Age Macular Degeneration- Alzheimer Disease : interest of Ophthalmologic Exam in Detection, Follow-up of AMD, of Alzheimer Disease, its relevance to highlight the Links and Correlations between AMD and AD. C Gonzalez, EURETINA 2013 37- Age Macular Degeneration- Alzheimer Disease In-Between Correlations: One Year Screening, Follow-Up and Outcome 4
C Gonzalez, EVER 2013 38- AMD Drusenoid deposits characterization: Interest of OCT, OCT en FACE C Gonzalez, EVER 2013 39 - Neovascular AMD with high recurrences and Atrophic Areas: Potential relationship between Neovascular complication and Atrophy C Gonzalez, EVER 2013 Europeans Publications in periodicals with reading committees 40 Retinal serous detachments. Interest of acetazolamide C Gonzalez. J.Fr. Ophtalmol., 1992 41 Study of contrast sensitivity in two groups of patients. Normal and amblyopic. C Gonzalez, C Labro-Leredde, Opthalmologies, 1999 42 Serous Drusen or micro-pigment epithelium detachment. Neovascular risk factor. C Gonzalez, Ophtalmologies, 1999 Communications 43 Subretinal new vessels treated by laser krypton photocoagulation. C Gonzalez, Société de Photocoagulation, 1987 44 Ocular fundus white spots C Gonzalez, Société Méditerranéenne du Midi, 1990 45 Antikeratin antibody profiling of retinal pigment epithelium cells C Gonzalez, Congrès international sur la macula, 1991 46 The high myopia new vessels. C Gonzalez, Congrès d Ophtalmologie, 1996 47 Interest of Thalidomide in the treatment of inflammation occuring with CMV chorioretinitis during VIH infection. C Gonzalez, M Obadia, S Averous, B Marchou, P Massip. Symposium «maladie à CMV au cours de l infection par le VIH», 1997 Nationals Publications in periodicals of specialty 48 The biometry : the iris, the retina : why, how, the ophthalmologist point of vue. C Gonzalez, Convergence, mai number, 2006 49 News, prospects, attitude about age macular degeneration ( AMD ) C Gonzalez, Journal Association Rétina France, february number, 2007 50 New prospects concerning medical retina C Gonzalez, Journal Association Rétina France, december number, 2008 Communication in meetings 51 Pigment epithelium degeneration :angiographic signs without complications C Gonzalez, SFO 1993 52 CMV Retinopathy, «what about Thalidomide?» C Gonzalez, M Obadia, SOIF, 1998 53 Late frame ICG hyperfluorescent pictures in AMD patients. C Gonzalez, SFO, 1999 54 New vessels and inflammation : clinical case report C Gonzalez, SOIE et SOIF, 2006 55 Interest and place of OCT in AMD and its neovascular complication follow-up C Gonzalez, SFO, 2007 5
56 Pegaptanib intravitreal injections (IVT) for the treatment of AMD previously treated by Dynamic Phototherapy ( PDT ). C Gonzalez, SFO, 2008 57 Recurrences features after loading inductive anti-vegf ranibizumab (Lucentis) treatment C Gonzalez, SFO, 2009 58 AMD edemas, spectral domain OCT Interest C Gonzalez, SFO, 2010 59 Treatment of focal and/or diffuse diabetic retinopathy macular edema by series of 3 intravitreal injections of ranibizumab C Gonzalez, SFO, 2011 60 Atrophic areas with Neovascular AMD: atrophic areas study interest, and their evolution, 3 years follow-up C Gonzalez, SFO, 2012 61 - Age Macular Degeneration- Alzheimer Disease : interest of Ophthalmologic Exam in Detection, Follow-up of Alzheimer Disease C Gonzalez, SFO, 2013 62- Age Macular Degeneration- Alzheimer Disease : Interest of OCT, OCT en face exam in detection and in follow-up of Alzheimer Disease C Gonzalez, SFO, 2013 Communications in specialist s meetings 63 Dynamic Phototherapy, one year and a half after The treatment and its indications. The follow-up and the re-treatment indications C Gonzalez, Spécialists in Ophtalmology meeting, 2002 64 AMD and therapeutic prospects C Gonzalez, Association Retina France meeting, 2002 65 Occult New vessels PDT interest for the treatment of foveolar subretinal occult neovascularisation C Gonzalez, Novavision, 2003 et 2004 66 Last research marchs for new vessels treatment. PDT interest for the treatment of subretinal occult new vessels C Gonzalez, Spécialists in Ophtalmology meeting, 2004 67 AMD and therapeutic prospects C Gonzalez, Spécialists in Ophtalmology meeting, 2004 68 OCT and AMD C Gonzalez, Spécialists in Ophtalmology meeting, 2005 69 AMD: clinical cases report 70 Angiography meeting 71 AMD : Follow-up, Prospect, Screening, Prévention 72 Angiogenesis: VEGF et anti-vegf (physiology & physiopathology) 73 - Anti- VEGF News C Gonzalez, FMC, 2007 74 - IVT unit in private practice and office C Gonzalez, DMLA en pratique, 2008 75 AMD and general practitioner C Gonzalez, FMC 2007 et 2010 ACTIVE MEMBER OF SCIENTIFIC GROUPS AND LEARNED SOCIETIES International AAO 6
ARVO EURETINA EVER EVRS SOE SOIE SOIF National SFO 7